The rhabdomyosarcoma market is expanding as unmet needs in pediatric and young-adult populations drive increased R&D and clinical activity. Additionally, the launch of emerging therapies such as Cabozantinib (Exelixis/Ipsen), PEEL-224 (Peel Therapeutics), Orotecan (Edison Oncology), […]
The rhabdomyosarcoma market is expanding as unmet needs in pediatric and young-adult populations drive increased R&D and clinical activity. Additionally, the launch of emerging therapies such as Cabozantinib (Exelixis/Ipsen), PEEL-224 (Peel Therapeutics), Orotecan (Edison Oncology), […]
